Ankylosing Spondylitis (Bekhterev's Disease) - Epidemiology Forecast - 2032

This ‘Ankylosing Spondylitis (AS) - Epidemiology Forecast-2032' report delivers an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS trends in the 7MM countries.

Ankylosing Spondylitis (AS) Disease Understanding

Ankylosing Spondylitis (AS) also called as Bechterew's disease is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. Clinical features of this group include inflammatory back pain, asymmetrical peripheral oligoarthritis (predominantly of the lower limbs), enthesitis, and specific organ involvement such as anterior uveitis, psoriasis, and chronic inflammatory bowel disease. Aortic root involvement and conduction abnormalities are rare complications of AS. AS affects men more often than women. General onset of AS commonly occurs in younger people, between the ages of 17 and 45. However, it can also affect children and those who are much older (Spondylitis association of america).

AS is a type of spondyloarthropathy (SpA) - Spondyloarthropathies are a family of related inflammatory rheumatic disorders which also include reactive arthritis (RA), psoriatic arthritis (PsA), spondyloarthropathy associated with inflammatory bowel disease (IBD), undifferentiated spondyloarthropathy (USpA), and, possibly, Whipple disease and Behçet disease - and is often found in association with other spondyloarthropathies, including ReA, PsA, ulcerative colitis (UC), and Crohn disease. It has also been found that such patients quite often have a family history of either AS or another spondyloarthropathy. Axial Spondyloarthritis or axial SpA (axSpA) refers to a particular form of spondyloarthritis in which the predominant symptom is inflammatory back pain. Axial SpA is further divided into two subgroups as Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Ankylosing Spondylitis (AS) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Ankylosing Spondylitis, Diagnosed Prevalent cases of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis scenario in the the 7MM countries from 2019 to 2032.

Ankylosing Spondylitis (AS) Detailed Epidemiology Segmentation

• Total prevalent population of AS in seven major markets is 2,282,664 in 2021. These cases are estimated to increase in the forecast period
• As per the estimates there were nearly 968,326 AS cases in EU-5 countries in 2021. Germany accounted for the highest number of cases in 2021, followed by Spain and United Kingdom.
• Among EU5 countries, Italy had the highest number of diagnosed prevalent cases for AS (191,566 cases), while UK had the least cases (54,634) in 2021.
• Total diagnosed prevalent cases of Ankylosing Spondylitis in Japan was found to be 4,095 in the year 2021.
• Total diagnosed prevalent cases of Ankylosing Spondylitis in Japan was found to be 4,095 in the year 2021.

Scope of the Report

• The report covers the descriptive overview of AS, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the historical and forecasted patient pool covering the 7MM countries. (US, EU5, Japan)
• The report assesses the disease risk and burden and highlights the unmet needs of the 7MM countries.
• The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM countries by Total Prevalent cases of Ankylosing Spondylitis, Diagnosed Prevalent cases of Ankylosing Spondylitis, Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis, and Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis

Report Highlights

• 11-Year Forecast of AS
• 7MM Coverage
• Total Prevalent cases of Ankylosing Spondylitis
• Diagnosed Prevalent cases of Ankylosing Spondylitis
• Gender-specific Diagnosed Prevalent cases of Ankylosing Spondylitis
• Age-specific Diagnosed Prevalent cases of Ankylosing Spondylitis
• Gene-specific Diagnosed Prevalent cases of Ankylosing Spondylitis

Key Questions Answered

• What are the disease risk, and burden of AS?
• What is the historical AS patient pool in the 7MM countries?
• What would be the forecasted patient pool of AS at the 7MM level?
• What will be the growth opportunities across the 7MM countries with respect to the patient population pertaining to AS?
• At what CAGR the population is expected to grow across the 7MM countries during the forecast period (2022-2032)?

Reasons to Buy

The AS report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM AS epidemiology forecast.
• The AS epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The AS epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032